Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

January 15, 2026

Study Completion Date

February 15, 2026

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (2)

Winship Cancer Center of Emory University, Atlanta

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Ohio State University Comprehensive Cancer Center

OTHER